EMERGENT BIOSOLUTIONS INC. Interest Expense Nonoperating
EMERGENT BIOSOLUTIONS INC. (EBS) reported Interest Expense Nonoperating of $10.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for the quarter ending 2026-06-30 was $10.00M, a 31.97% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for the quarter ending 2026-03-31 was $11.00M, a 25.17% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for the quarter ending 2025-12-31 was $14.70M, a 0.68% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for the quarter ending 2025-09-30 was $15.20M, a 83.13% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for fiscal 2025 was $59.30M, a 16.48% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for fiscal 2024 was $71.00M, a 19.23% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for fiscal 2023 was $87.90M, a 135.66% increase from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. interest expense nonoperating for fiscal 2022 was $37.30M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.00M 10-Q · filed 2026-08-06 | $21.00M 10-Q · filed 2026-08-06 | $35.70M derived: sum of 3 quarters · filed 2026-08-06 | $50.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.00M 10-Q · filed 2026-05-01 | $25.70M derived: sum of 2 quarters · filed 2026-05-01 | $40.90M derived: sum of 3 quarters · filed 2026-05-01 | $55.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $14.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $29.90M derived: sum of 2 quarters · filed 2026-02-27 | $44.60M derived: sum of 3 quarters · filed 2026-08-06 | $59.30M 10-K · filed 2026-02-27 |
| 2025-09-30 | $15.20M 10-Q · filed 2025-10-30 | $29.90M derived: sum of 2 quarters · filed 2026-08-06 | $44.60M 10-Q · filed 2025-10-30 | $59.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $14.70M 10-Q · filed 2026-08-06 | $29.40M 10-Q · filed 2026-08-06 | $44.20M derived: sum of 3 quarters · filed 2026-08-06 | $52.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $14.70M 10-Q · filed 2026-05-01 | $29.50M derived: sum of 2 quarters · filed 2026-05-01 | $37.80M derived: sum of 3 quarters · filed 2026-05-01 | $61.40M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $14.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $23.10M derived: sum of 2 quarters · filed 2026-02-27 | $46.70M derived: sum of 3 quarters · filed 2026-02-27 | $71.00M 10-K · filed 2026-02-27 |
| 2024-09-30 | $8.30M 10-Q · filed 2025-10-30 | $31.90M derived: sum of 2 quarters · filed 2025-10-30 | $56.20M 10-Q · filed 2025-10-30 | $77.90M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $23.60M 10-Q · filed 2025-08-07 | $47.90M 10-Q · filed 2025-08-07 | $69.60M derived: sum of 3 quarters · filed 2026-02-27 | $89.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $24.30M 10-Q · filed 2025-05-08 | $46.00M derived: sum of 2 quarters · filed 2026-02-27 | $65.70M derived: sum of 3 quarters · filed 2026-02-27 | $94.30M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $21.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $41.40M derived: sum of 2 quarters · filed 2026-02-27 | $70.00M derived: sum of 3 quarters · filed 2026-02-27 | $87.90M 10-K · filed 2026-02-27 |
| 2023-09-30 | $19.70M 10-Q · filed 2024-11-07 | $48.30M derived: sum of 2 quarters · filed 2024-11-07 | $66.20M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $28.60M 10-Q · filed 2024-08-07 | $46.50M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $37.30M 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |